The management of tuberculosis: Epidemiology, resistance and monitoring

Danish Medical Bulletin

Volumn 57, Issue 11, 2010, Pages 1-19

  Bang, Didi ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CAPREOMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING) A; DNA TOPOISOMERASE (ATP HYDROLYSING) B; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; KATG PROTEIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA POLYMERASE BETA SUBUNIT; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; DISEASE TRANSMISSION; DNA MICROARRAY; DNA SEQUENCE; DRUG MONITORING; DRUG SENSITIVITY; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENE MUTATION; GENOTYPE; HUMAN; INFORMATION PROCESSING; LIQUID CHROMATOGRAPHY; LONG TERM CARE; MOLECULAR BEACON; MULTIDRUG RESISTANT TUBERCULOSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENT INFECTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SHORT COURSE THERAPY; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 78649585841     PISSN: 16039629     EISSN: 16039629     Source Type: Journal    
DOI: None     Document Type: Article

References (138)

1. EPI-NEWS. National surveillance of communicable diseases. Tuberculosis. Copenhagen: Department of Epidemiology, Statens Serum Institut; 1992-2008.
2. Poulsen S, Ronne T, Kok-Jensen A, Bauer JO, Miorner H. Tuberculosis in Denmark 1972-1996. Ugeskr Laeger 1999;161:3452-7.
3. World Health Organization. Global tuberculosis control. A short update to the 2009 report. WHO/HTM/TB/2009.426. Geneva: WHO; 2009.
4. World Health Organization. Treatment of tuberculosis. Guidelines for National Programmes, 3rd. edition. WHO/CDC/TB/2003.313. Geneva: WHO; 2003.
5. Fine PE, Small PM. Exogenous reinfection in tuberculosis. N Engl J Med 1999;341:1226-7.
6. Dobler CC, Marks GB, Simpson SE, Crawford AB. Recurrence of tuberculosis at a Sydney chest clinic between 1994 and 2006: reactivation or reinfection? Med J Aust 2008;188:153-5.
7. Cacho J, Perez MA, Cano I, Soria T, Ramos MA, Sanchez CM, et al. Recurrent tuberculosis from 1992 to 2004 in a metropolitan area. Eur Respir J 2007;30:333-7.
8. Bandera A, Gori A, Catozzi L, Degli EA, Marchetti G, Molteni C, et al. Molecular epidemiology study of exogenous reinfection in an area with a low incidence of tuberculosis. J Clin Microbiol 2001;39:2213-8.
9. Caminero JA, Pena MJ, Campos-Herrero MI, Rodriguez JC, Afonso O, Martin C, et al. Exogenous reinfection with tuberculosis on a European island with a moderate incidence of disease. Am J Respir Crit Care Med 2001;163:717-20.
10. Sonnenberg P, Murray J, Glynn JR, Shearer S, Kambashi B, Godfrey-Faussett P. HIV-1 and recurrence, relapse, and reinfection of tuberculosis after cure: a cohort study in South African mineworkers. Lancet 2001;358:1687-93.
11. van Rie A, Warren R, Richardson M, Victor TC, Gie RP, Enarson DA, et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-9.
12. Bloom BR. Tuberculosis. Pathogenesis, Protection and Control. Washington: ASM Press; 1994.
13. Al Moamary MS, Black W, Bessuille E, Elwood RK, Vedal S. The significance of the persistent presence of acidfast bacilli in sputum smears in pulmonary tuberculosis. Chest 1999;116:726-31.
14. Kim TC, Blackman RS, Heatwole KM, Kim T, Rochester DF. Acid-fast bacilli in sputum smears of patients with pulmonary tuberculosis. Prevalence and significance of negative smears pretreatment and positive smears post-treatment. Am Rev Respir Dis 1984;129:264-8.
15. Nelson SM, Deike MA, Cartwright CP. Value of examining multiple sputum specimens in the diagnosis of pulmonary tuberculosis. J Clin Microbiol 1998;36:467-9.
16. Harvell JD, Hadley WK, Ng VL. Increased sensitivity of the BACTEC 460 mycobacterial radiometric broth culture system does not decrease the number of respiratory specimens required for a definitive diagnosis of pulmonary tuberculosis. J Clin Microbiol 2000;38:3608-11.
17. American Thoracic Society/Centers for Disease Control and Prevention of Infectious Diseases Society of America. Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62.
18. Mitchison DA. Assessment of new sterilizing drugs for treating pulmonary tuberculosis by culture at 2 months. Am Rev Respir Dis 1993;147:1062-3.
19. Mukherjee JS, Rich ML, Socci AR, Joseph JK, Viru FA, Shin SS, et al. Programmes and principles in treatment of multidrug-resistant tuberculosis. Lancet 2004;363:474-81.
20. Goble M, Iseman MD, Madsen LA, Waite D, Ackerson L, Horsburgh CR, Jr. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993;328:527-32.
21. World Health Organization. Guidelines for the programatic management of drug-resistant tuberculosis. Emergency update. WHO/HTM/ TB/2008.402. Geneva: WHO 2008.
22. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, et al. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann Intern Med 2006;144:650-9.
23. World Health Organization. Anti-tuberculosis drug resistance in the world. Report No. 4. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO/HTM/TB/2008.394. Geneva: WHO; 2008.
24. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 1993;341:647-50.
25. Hillemann D, Kubica T, Agzamova R, Venera B, Rusch-Gerdes S, Niemann S. Rifampicin and isoniazid resistance mutations in Mycobacterium tuberculosis strains isolated from patients in Kazakhstan. Int J Tuberc Lung Dis 2005;9:1161-7.
26. Musser JM, Kapur V, Williams DL, Kreiswirth BN, van Soolingen D, van Embden JD. Characterization of the catalase-peroxidase gene (katG) and inhA locus in isoniazid- resistant and -susceptible strains of Mycobacterium tuberculosis by automated DNA sequencing: restricted array of mutations associated with drug resistance. J Infect Dis 1996;173:196-202.
27. Zhang M, Yue J, Yang YP, Zhang HM, Lei JQ, Jin RL, et al. Detection of mutations associated with isoniazid resistance in Mycobacterium tuberculosis isolates from China. J Clin Microbiol 2005;43:5477-82.
28. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997;35:719-23.
29. Revised international definitions in tuberculosis control. Int J Tuberc Lung Dis 2001;5:213-5.
30. Kok-Jensen A, Thuesen Pedersen J, Taudorf E, Viskum, K. The National Tuberculosis Program and Proposed Clinical Management of Tuberculosis. Consensus report no. 11. Copenhagen: The Danish Lung Association/The Danish Medical Association; 2000.
31. Veen J, Raviglione M, Rieder HL, Migliori GB, Graf P, Grzemska M, et al. Standardized tuberculosis treatment outcome monitoring in Europe. Recommendations of a Working Group of the World Health Organization (WHO) and the European Region of the International Union Against Tuberculosis and Lung Disease (IUATLD) for uniform reporting by cohort analysis of treatment outcome in tuberculosis patients. Eur Respir J 1998;12:505-10.
32. Jasmer RM, Bozeman L, Schwartzman K, Cave MD, Saukkonen JJ, Metchock B, et al. Recurrent tuberculosis in the United States and Canada: relapse or reinfection? Am J Respir Crit Care Med 2004;170:1360-6.
33. Garcia DV, Marin M, Hernangomez S, Diaz M, Ruiz Serrano MJ, Alcala L, et al. Tuberculosis recurrences: reinfection plays a role in a population whose clinical/ epidemiological characteristics do not favor reinfection. Arch Intern Med 2002;162:1873-9.
34. de Boer AS, Borgdorff MW, Vynnycky E, Sebek MM, van Soolingen D. Exogenous re-infection as a cause of recurrent tuberculosis in a low-incidence area. Int J Tuberc Lung Dis 2003;7:145-52.
35. El Sahly HM, Wright JA, Soini H, Bui TT, Williams-Bouyer N, Escalante P, et al. Recurrent tuberculosis in Houston, Texas: a population-based study. Int J Tuberc Lung Dis 2004;8:333-40.
36. Heldal E, Docker H, Caugant DA, Tverdal A. Pulmonary tuberculosis in Norwegian patients. The role of reactivation, re-infection and primary infection assessed by previous mass screening data and restriction fragment length polymorphism analysis. Int J Tuberc Lung Dis 2000;4:300-7.
37. Panjabi R, Comstock GW, Golub JE. Recurrent tuberculosis and its risk factors: adequately treated patients are still at high risk. Int J Tuberc Lung Dis 2007;11:828-37.
38. Cox HS, Morrow M, Deutschmann PW. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 2008;336:484-7.
39. Nettles RE, Mazo D, Alwood K, Gachuhi R, Maltas G, Wendel K, et al. Risk factors for relapse and acquired rifamycin resistance after directly observed tuberculosis treatment: a comparison by HIV serostatus and rifamycin use. Clin Infect Dis 2004;38:731-6.
40. Palaci M, Dietze R, Hadad DJ, Ribeiro FK, Peres RL, Vinhas SA, et al. Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol 2007;45:4064-6.
41. Gillespie SH. Evolution of drug resistance in Mycobacterium tuberculosis: clinical and molecular perspective. Antimicrob Agents Chemother 2002;46:267-74.
42. Zhang Y, Yew WW. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:1320-30.
43. Richardson ET, Lin SY, Pinsky BA, Desmond E, Banaei N. First documentation of isoniazid reversion in Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009;13:1347-54.
44. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB). Global report on surveillance and response. WHO/ HTM/TB/2010.3. Geneva: WHO; 2010.
45. World Health Organization. Treatment of tuberculosis. Guidelines for National Programmes, 4th. edition. WHO/CDC/TB/2009.420. Geneva: WHO; 2009.
46. Thomsen VO, Bauer J, Lillebaek T, Glismann S. Results from 8 yrs of susceptibility testing of clinical Mycobacterium tuberculosis isolates in Denmark. Eur Respir J 2000;16:203-8.
47. World Health Organization. Guidelines for the Management of Drug-resistant tuberculosis. WHO/HTM/96.210(Rev.1). Geneva: WHO; 1997.
48. Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. JAMA 2000;283:2537-45.
49. Eker B, Ortmann J, Migliori GB, Sotgiu G, Muetterlein R, Centis R, et al. Multidrug- and extensively drug-resistant tuberculosis, Germany. Emerg Infect Dis 2008;14:1700-6.
50. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, et al. Treatment and outcome analysis of 205 patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-9.
51. Avendano M, Goldstein RS. Multidrug-resistant tuberculosis: long term follow-up of 40 non-HIV-infected patients. Can Respir J 2000;7:383-9.
52. Viskum K, Kok-Jensen A. Multidrug-resistant tuberculosis in Denmark 1993-1995. Int J Tuberc Lung Dis. 1997;1:299-301.
53. Hutchison DC, Drobniewski FA, Milburn HJ. Management of multiple drug-resistant tuberculosis. Respir Med 2003;97:65-70.
54. Geerligs WA, Van Altena R, De Lange WCM, van Soolingen D, Van Der Werf TS. Multidrug-resistant tuberculosis: long-term treatment outcome in the Netherlands. Int J Tuberc Lung Dis 2000;4:758-64.
55. Telzak EE, Sepkowitz K, Alpert P, Mannheimer S, Medard F, El Sadr W, et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995;333:907-11.
56. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009;4:e6914.
57. Turett GS, Telzak EE, Torian LV, Blum S, Alland D, Weisfuse I, et al. Improved outcomes for patients with multidrug- resistant tuberculosis. Clin Infect Dis 1995;21:1238-44.
58. Fortun J, Martin-Davila P, Molina A, Navas E, Hermida JM, Cobo J, et al. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J Antimicrob Chemother 2007;59:794-8.
59. Chan ED, Strand MJ, Iseman MD. Treatment outcomes in extensively resistant tuberculosis. N Engl J Med 2008;359:657-9.
60. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006;368:1575-80.
61. Leimane V, Dravniece G, Riekstina V, Sture I, Kammerer S, Chen MP, et al. Treatment outcome of multidrug/ extensively drug-resistant tuberculosis in Latvia, 2000-2004. Eur Respir J 2010; Feb 25 [Epub ahead of print].
62. Farah MG, Tverdal A, Steen TW, Heldal E, Brantsaeter AB, Bjune G. Treatment outcome of new culture positive pulmonary tuberculosis in Norway. BMC Public Health 2005;5:14.
63. Lillebaek T, Poulsen S, Kok-Jensen A. Tuberculosis treatment in Denmark: treatment outcome for all Danish patients in 1992. Int J Tuberc Lung Dis 1999;3:603-12.
64. Cattamanchi A, Dantes RB, Metcalfe JZ, Jarlsberg LG, Grinsdale J, Kawamura LM, et al. Clinical characteristics and treatment outcomes of patients with isoniazidmonoresistant tuberculosis. Clin Infect Dis 2009;48:179-85.
65. Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009;9:153-61.
66. Chan ED, Iseman MD. Multidrug-resistant and extensively drug-resistant tuberculosis: a review. Curr Opin Infect Dis 2008;21:587-95.
67. Katiyar SK, Bihari S, Prakash S, Mamtani M, Kulkarni H. A randomised controlled trial of high-dose isoniazid adjuvant therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2008;12:139-45.
68. Moulding TS. Should isoniazid be used in retreatment of tuberculosis despite acquired isoniazid resistance? Am Rev Respir Dis 1981;123:262-4.
69. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-80.
70. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F. Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-99.
71. Clinical and Laboratory Standards Institute. Susceptibility testing of Mycobacteria, Nocardiae, and other Aerobic Actinomycetes; approved Standard M24-A. Wayne, Pennsylvania: CLSI; 2003.
72. World Health Organization. Policy guidance on drugsusceptibility testing (DST) of second-line antituberculous drugs. WHO/HTM/ TB/2008.392. Geneva: WHO; 2008.
73. Weis SE, Slocum PC, Blais FX, King B, Nunn M, Matney GB, et al. The effect of directly observed therapy on the rates of drug resistance and relapse in tuberculosis. N Engl J Med 1994;330:1179-84.
74. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin. Microbiol 2005;43:3699-703.
75. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with lowand high-level resistance. J Clin Microbiol 2006;44:3659-64.
76. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM. Use of Genotype MTBDR assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical strains isolated in Italy. J Clin.Microbiol 2006;44:2485-91.
77. Hillemann D, Rusch-Gerdes S, Richter E. Application of the Genotype MTBDR assay directly on sputum specimens. Int J Tuberc Lung Dis 2006;10:1057-9.
78. Somoskovi A, Dormandy J, Mitsani D, Rivenburg J, Salfinger M. Use of smear-positive samples to assess the PCR-based genotype MTBDR assay for rapid, direct detection of the Mycobacterium tuberculosis complex as well as its resistance to isoniazid and rifampin. J Clin Microbiol 2006;44:4459-63.
79. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of Multidrugresistant tuberculosis (MDR-TB). Policy statement. Geneva: WHO; 2008.
80. GenoType® MTBDR protocol. Hain Life science GmbH, Nehren, Germany.
81. Morgan M, Kalantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005;5:62.
82. Cavusoglu C, Turhan A, Akinci P, Soyler I. Evaluation of the Genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol 2006;44:2338-42.
83. Makinen J, Marttila HJ, Marjamaki M, Viljanen MK, Soini H. Comparison of two commercially available DNA line probe assays for detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2006;44:350-2.
84. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008;32:1165-74.
85. Brossier F, Veziris N, Jarlier V, Sougakoff W. Performance of MTBDR plus for detecting high/low levels of Mycobacterium tuberculosis resistance to isoniazid. Int J Tuberc Lung Dis 2009;13:260-5.
86. Lacoma A, Garcia-Sierra N, Prat C, Ruiz-Manzano J, Haba L, Roses S, et al. GenoType MTBDRplus assay for molecular detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis strains and clinical samples. J Clin Microbiol 2008;46:3660-7.
87. Causse M, Ruiz P, Gutierrez JB, Zerolo J, Casal M. Evaluation of new GenoType MTBDRplus for detection of resistance in cultures and direct specimens of Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2008;12:1456-60.
88. Huang WL, Chen HY, Kuo YM, Jou R. Performance assessment of the GenoType MTBDRplus test and DNA sequencing in detection of multidrug-resistant Mycobacterium tuberculosis. J Clin Microbiol 2009;47:2520-4.
89. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007;45:2635-40.
90. Barnard M, Albert H, Coetzee G, O'Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008;177:787-92.
91. Evans J, Stead MC, Nicol MP, Segal H. Rapid genotypic assays to identify drug-resistant Mycobacterium tuberculosis in South Africa. J Antimicrob Chemother 2009;63:11-6.
92. Nikolayevskyy V, Balabanova Y, Simak T, Malomanova N, Fedorin I, Drobniewski F. Performance of the Genotype MTBDRPlus assay in the diagnosis of tuberculosis and drug resistance in Samara, Russian Federation. BMC Clin Pathol 2009;9:2.
93. Albert H, Bwanga F, Mukkada S, Nyesiga B, Ademun JP, Lukyamuzi G, et al. Rapid screening of MDR-TB using molecular Line Probe Assay is feasible in Uganda. BMC Infect Dis 2010;10:41.
94. Gryadunov D, Mikhailovich V, Lapa S, Roudinskii N, Donnikov M, Pan'kov S, et al. Evaluation of hybridisation on oligonucleotide micro-arrays for analysis of drug-resistant Mycobacterium tuberculosis. Clin Microbiol Infect 2005;11:531-9.
95. Caoili JC, Mayorova A, Sikes D, Hickman L, Plikaytis BB, Shinnick TM. Evaluation of the TB-Biochip oligonucleotide microarray system for rapid detection of rifampin resistance in Mycobacterium tuberculosis. J Clin Microbiol 2006;44:2378-81.
96. Kim SY, Park YJ, Song E, Jang H, Kim C, Yoo J, et al. Evaluation of the CombiChip Mycobacteria drug resistance detection DNA chip for identifying mutations associated with resistance to isoniazid and rifampin in Mycobacterium tuberculosis. Diagn Microbiol Infect Dis 2006;54:203-10.
97. Park H, Song EJ, Song ES, Lee EY, Kim CM, Jeong SH, et al. Comparison of a conventional antimicrobial susceptibility assay to an oligonucleotide chip system for detection of drug resistance in Mycobacterium tuberculosis isolates. J Clin Microbiol 2006;44:1619-24.
98. Jureen P, Engstrand L, Eriksson S, Alderborn A, Krabbe M, Hoffner SE. Rapid detection of rifampin resistance in Mycobacterium tuberculosis by Pyrosequencing technology. J Clin Microbiol 2006;44:1925-9.
99. Halse TA, Edwards J, Cunningham PL, Wolfgang WJ, Dumas NB, Escuyer VE et al. Combined real-time PCR and rpoB gene Pyrosequencing for the rapid identification of Mycobacterium tuberculosis and the determination of rifampin resistance, directly on clinical specimens. J Clin Microbiol 2010;48:1182-8.
100. Piatek AS, Telenti A, Murray MR, El Hajj H, Jacobs WR, Kramer FR, et al. Genotypic analysis of Mycobacterium tuberculosis in two distinct populations using molecular beacons: implications for rapid susceptibility testing. Antimicrob Agents Chemother 2000;44:103-10.
101. Lin SY, Probert W, Lo M, Desmond E. Rapid detection of isoniazid and rifampin resistance mutations in Mycobacterium tuberculosis complex from cultures or smearpositive sputa by use of molecular beacons. J Clin Microbiol 2004;42:4204-8.
102. El Hajj HH, Marras SA, Tyagi S, Kramer FR, Alland D. Detection of rifampin resistance in Mycobacterium tuberculosis in a single tube with molecular beacons. J Clin Microbiol 2001;39:4131-7.
103. Helb D, Jones M, Story E, Boehme C, Wallace E, Ho K, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010;48:229-37.
104. Espasa M, Gonzalez-Martin J, Alcaide F, Aragon LM, Lonca J, Manterola JM, et al. Direct detection in clinical samples of multiple gene mutations causing resistance of Mycobacterium tuberculosis to isoniazid and rifampicin using fluorogenic probes. J Antimicrob Chemother 2005;55:860-5.
105. Wada T, Maeda S, Tamaru A, Imai S, Hase A, Kobayashi K. Dual-probe assay for rapid detection of drug-resistant Mycobacterium tuberculosis by real-time PCR. J Clin Microbiol 2004;42:5277-85.
106. van Doorn HR, Claas EC, Templeton KE, van der Zanden AG, te K, V, de Jong MD, et al. Detection of a point mu tation associated with high-level isoniazid resistance in Mycobacterium tuberculosis by using real-time PCR technology with 3'-minor groove binder-DNA probes. J Clin Microbiol 2003;41:4630-5.
107. Torres MJ, Criado A, Palomares JC, Aznar J. Use of realtime PCR and fluorimetry for rapid detection of rifampin and isoniazid resistance-associated mutations in Mycobacterium tuberculosis. J Clin Microbiol 2000;38:3194-9.
108. Torres MJ, Criado A, Ruiz M, Llanos AC, Palomares JC, Aznar J. Improved real-time PCR for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis clinical isolates. Diagn Microbiol Infect Dis 2003;45:207-12.
109. Garcia D, V, del SD, I, Lasala F, Chaves F, Alcala L, Bouza E. New real-time PCR able to detect in a single tube multiple rifampin resistance mutations and high-level isoniazid resistance mutations in Mycobacterium tuberculosis. J Clin Microbiol 2002;40:988-95.
110. Saribas Z, Yurdakul P, Alp A, Gunalp A. Use of fluorescence resonance energy transfer for rapid detection of isoniazid resistance in Mycobacterium tuberculosis clinical isolates. Int J Tuberc Lung Dis 2005;9:181-7.
111. Marin M, Garcia DV, Ruiz-Serrano MJ, Bouza E. Rapid direct detection of multiple rifampin and isoniazid resistance mutations in Mycobacterium tuberculosis in respiratory samples by real-time PCR. Antimicrob Agents Chemother 2004;48:4293-300.
112. Ruiz M, Torres MJ, Llanos AC, Arroyo A, Palomares JC, Aznar J. Direct detection of rifampin- and isoniazidresistant Mycobacterium tuberculosis in auraminerhodamine- positive sputum specimens by real-time PCR. J Clin.Microbiol 2004;42:1585-9.
113. Silva MS, Senna SG, Ribeiro MO, Valim AR, Telles MA, Kritski A, et al. Mutations in katG, inhA, and ahpC genes of Brazilian isoniazid-resistant isolates of Mycobacterium tuberculosis. J Clin Microbiol 2003;41:4471-4.
114. Cheng X, Zhang J, Yang L, Xu X, Liu J, Yu W, et al. A new multi-PCR-SSCP assay for simultaneous detection of isoniazid and rifampin resistance in Mycobacterium tuberculosis. J Microbiol Methods 2007;70:301-5.
115. Tracevska T, Jansone I, Broka L, Marga O, Baumanis V. Mutations in the rpoB and katG genes leading to drug resistance in Mycobacterium tuberculosis in Latvia. J Clin Microbiol 2002;40:3789-92.
116. Scarpellini P, Braglia S, Carrera P, Cedri M, Cichero P, Colombo A, et al. Detection of rifampin resistance in Mycobacterium tuberculosis by double gradientdenaturing gradient gel electrophoresis. Antimicrob Agents Chemother 1999;43:2550-4.
117. Siddiqi SH, Libonati JP, Middlebrook G. Evaluation of rapid radiometric method for drug susceptibility testing of Mycobacterium tuberculosis. J Clin.Microbiol 1981;13:908-12.
118. Van Deun A, Barrera L, Bastian I, Fattorini L, Hoffmann H, Kam KM, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009;47:3501-6.
119. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J 2005;25:564-9.
120. Anthony RM, Cobelens FG, Gebhard A, Klatser PR, Lumb R, Rusch-Gerdes S, et al. Liquid culture for Mycobacterium tuberculosis: proceed, but with caution. Int J Tuberc Lung Dis 2009;13:1051-3.
121. Moore DA, Evans CA, Gilman RH, Caviedes L, Coronel J, Vivar A, et al. Microscopic-observation drugsusceptibility assay for the diagnosis of TB. N Engl J Med 2006;355:1539-50.
122. Hamid SA, Aung KJ, Hossain MA, Van Deun A. Early and rapid microscopy-based diagnosis of true treatment failure and MDR-TB. Int J Tuberc Lung Dis 2006;10:1248-54.
123. Robledo J, Mejia GI, Paniagua L, Martin A, Guzman A. Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis by the direct thin-layer agar method. Int J Tuberc Lung Dis 2008;12:1482-4.
124. Martin A, Portaels F, Palomino JC. Colorimetric redoxindicator methods for the rapid detection of multidrug resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. J Antimicrob Chemother 2007;59:175-83.
125. Martin A, Panaiotov S, Portaels F, Hoffner S, Palomino JC, Angeby K. The nitrate reductase assay for the rapid detection of isoniazid and rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta- analysis. J Antimicrob Chemother 2008;62:56-64.
126. Martin A, Palomino JC, Portaels F. Rapid detection of ofloxacin resistance in Mycobacterium tuberculosis by two low-cost colorimetric methods: resazurin and nitrate reductase assays. J Clin Microbiol 2005;43:1612-6.
127. Pai M, Kalantri S, Pascopella L, Riley LW, Reingold AL. Bacteriophage-based assays for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a meta-analysis. J Infect 2005;51:175-87.
128. Bardarov S, Dou H, Eisenach K, Banaiee N, Ya S, Chan J, et al. Detection and drug-susceptibility testing of Mycobacterium tuberculosis from sputum samples using luciferase reporter phage: comparison with the Mycobacteria Growth Indicator Tube (MGIT) system. Diagn Microbiol Infect Dis 2003;45:53-61.
129. Albert H, Trollip A, Seaman T, Mole RJ. Simple, phagebased (FASTP-plaque) technology to determine rifampicin resistance of Mycobacterium tuberculosis directly from sputum. Int J Tuberc Lung Dis 2004;8:1114-9.
130. Butt T, Ahmad RN, Afzal RK, Mahmood A, Anwar M. Rapid detection of rifampicin susceptibility of Mycobacterium tuberculosis in sputum specimens by mycobacteriophage assay. J Pak Med Assoc 2004;54:379-82.
131. Williams DL, Spring L, Collins L, Miller LP, Heifets LB, Gangadharam PR, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998;42:1853-7.
132. Ma X, Wang H, Deng Y, Liu Z, Xu Y, Pan X, et al. rpoB gene mutations and molecular characterization of rifampin- resistant Mycobacterium tuberculosis isolates from Shandong Province, China. J Clin Microbiol 2006;44:3409-12.
133. Sandgren A, Strong M, Muthukrishnan P, Weiner BK, Church GM, Murray MB. Tuberculosis drug resistance mutation database. PLoS Med 2009;6:e2.
134. Ho YM, Sun YJ, Wong SY, Lee AS. Contribution of dfrA and inhA mutations to the detection of isoniazidresistant Mycobacterium tuberculosis isolates. Antimicrob Agents Chemother 2009;53:4010-2.
135. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin- capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009;47:1767-72.
136. Brossier F, Veziris N, Aubry A, Jarlier V, Sougakoff W. Detection by Genotype MTBDRsl test of complex resistance mechanisms to second-line drugs and ethambutol in multidrug-resistant Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2010;48:1683-9.
137. American Thoracic Society. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175:367-416.
138. Bang D, Herlin T, Stegger M, Andersen AB, Torkko P, Tortoli E, et al. Mycobacterium arosiense sp. nov., a slowly growing, scotochromogenic species causing osteomyelitis in an immunocompromised child. Int J Syst Evol Microbiol 2008;58:2398-40.